<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>SMITHKLINE SELLS PRODUCT LINES</title>
    <meta content="MB003221" name="slug"/>
    <meta content="1" name="publication_day_of_month"/>
    <meta content="9" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Friday" name="publication_day_of_week"/>
    <meta content="Business/Financial Desk" name="dsk"/>
    <meta content="4" name="print_page_number"/>
    <meta content="C" name="print_section"/>
    <meta content="3" name="print_column"/>
    <meta content="Business" name="online_sections"/>
    <docdata>
      <doc-id id-string="1226888"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <series series.name="WORLD BUSINESS BRIEFING: EUROPE"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Mergers, Acquisitions and Divestitures</classifier>
        <org class="indexing_service">Smithkline Beecham Plc</org>
        <org class="indexing_service">Glaxo Wellcome Plc</org>
        <org class="indexing_service">Novartis Ag</org>
        <org class="indexing_service">Roche Holding Ag</org>
        <person class="indexing_service">Kapner, Suzanne</person>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Business/World Business</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Classifieds/Job Market/Job Categories/Pharmaceutical, Biotechnology and Science</classifier>
        <classifier class="online_producer" type="general_descriptor">Mergers, Acquisitions and Divestitures</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Finances</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000901T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9505E7DB1230F932A3575AC0A9669C8B63" item-length="160" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>SMITHKLINE SELLS PRODUCT LINES</hl1>
      </hedline>
      <byline class="print_byline">By Suzanne Kapner</byline>
      <byline class="normalized_byline">Kapner, Suzanne</byline>
      <abstract>
        <p>SmithKline Beecham PLC, seeking to win regulatory approval for its merger with Glaxo Wellcome PLC, says it will sell drug lines to Novartis AG and Roche Holding AG for almost $2.9 billion (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>In an effort to win regulatory approval for its merger with Glaxo Wellcome P.L.C., SmithKline Beecham P.L.C. said it would sell product lines to Novartis A.G. and Roche Holding A.G. for almost $2.9 billion. Novartis will buy SmithKline's herpes treatments Famvir and Vectavir/Denavir for $1.63 billion, while Roche will pay $1.23 billion for Kytril, an antinausea drug for cancer patients. SmithKline, based in Britain, must sell some of its drugs to gain approval for its merger with Glaxo Wellcome, also of Britain, because Glaxo makes similar products. The sales are contingent on the completion of the $75 billion merger, which is expected to close next month.</p>
        <p>Suzanne Kapner (NYT)</p>
      </block>
      <block class="full_text">
        <p>In an effort to win regulatory approval for its merger with Glaxo Wellcome P.L.C., SmithKline Beecham P.L.C. said it would sell product lines to Novartis A.G. and Roche Holding A.G. for almost $2.9 billion. Novartis will buy SmithKline's herpes treatments Famvir and Vectavir/Denavir for $1.63 billion, while Roche will pay $1.23 billion for Kytril, an antinausea drug for cancer patients. SmithKline, based in Britain, must sell some of its drugs to gain approval for its merger with Glaxo Wellcome, also of Britain, because Glaxo makes similar products. The sales are contingent on the completion of the $75 billion merger, which is expected to close next month.</p>
        <p>Suzanne Kapner (NYT)</p>
        <p>WORLD BUSINESS BRIEFING: EUROPE</p>
      </block>
    </body.content>
  </body>
</nitf>
